WHO Unveils 10-Year Global Roadmap to Combat Pregnancy Hypertension and Pre-Eclampsia Mortality

The World Health Organization and its global partners have launched a comprehensive 10-year roadmap to overhaul how health systems predict, detect, and treat hypertensive disorders during pregnancy. Covering the period from 2026 to 2035, the initiative directs governments, funders, and pharmaceutical developers to close a chronic innovation gap that leaves millions of women vulnerable.[1][4]

Hypertensive disorders, which include pre-eclampsia and eclampsia, complicate an estimated 10 to 15 percent of pregnancies worldwide. They currently account for around 16 percent of maternal deaths globally, resulting in approximately 42,000 maternal fatalities each year despite being largely preventable with proper medical intervention.[1][2]

Beyond the devastating toll on mothers, these conditions also cause more than 500,000 stillbirths and newborn deaths annually. The burden falls disproportionately on women and babies in low- and middle-income countries, where timely access to quality prevention, accurate diagnosis, and effective treatment is often severely limited by systemic resource constraints.[4][5][6]

"Pre-eclampsia can develop in any pregnancy," said Dr. Pascale Allotey, director of the WHO's Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing. "Whether it becomes fatal depends on whether a woman's blood pressure was checked in time, and whether quality emergency care was within reach when it turned severe."[1][2]

Closing the Innovation Gap

The roadmap highlights a striking disparity between the massive global scale of the problem and the lack of medicines specifically developed and approved by regulators for pre-eclampsia. Research investment has historically focused on diagnostics, leaving a chronic underinvestment in new preventive and treatment options that could halt the progression of the disease.[1][3][5]

The WHO notes that while significant progress has been made against other major causes of maternal mortality, deaths from hypertensive disorders have declined far too slowly over the past three decades. This persistent stagnation prompted the coordinated global action plan, which was officially launched at the Society for Maternal-Fetal Medicine Global Conference.[1][2][4]

In many developing nations, pregnant women still lack reliable access to basic blood pressure measurement and routine urine protein testing. They also face critical shortages of essential medicines, including aspirin, antihypertensives, and magnesium sulfate, which are absolutely critical for managing severe cases and preventing life-threatening seizures.[1][3][5][6]

Weak referral systems, severe shortages of trained health workers, and limited emergency obstetric services further delay life-saving care when complications arise. To address these systemic failures, the roadmap seeks to coordinate action across five interconnected areas: research and innovation, norms and standards, access to quality health products, implementation, and advocacy.[1][3][4]

Long-Term Cardiovascular Risks

The physical consequences of hypertensive disorders extend far beyond childbirth and the immediate postpartum recovery period. Women affected by these conditions face significantly increased risks of developing chronic hypertension, cardiovascular disease, stroke, and kidney disease later in life, requiring ongoing medical surveillance long after their pregnancy ends.[1][2]

Children exposed to pre-eclampsia during pregnancy also face elevated health risks, primarily those associated with preterm birth and low birth weight. Furthermore, these children are more susceptible to longer-term cardiovascular and metabolic diseases as they grow older, compounding the generational health impact of these untreated maternal conditions.[1][4][5]

To guide future investment and establish a clear baseline, the WHO convened more than 140 partners at a global summit in Kigali, Rwanda, in May 2026. That summit successfully identified 20 priority research questions designed to help clinicians predict, detect, and treat hypertensive disorders in pregnancy much more effectively.[1][4][5]

The resulting 74-page roadmap synthesizes the diverse perspectives of women with lived experience, clinical researchers, frontline health workers, professional associations, and international organizations. It emphasizes that progress in any single area will not be enough to reduce mortality rates without simultaneous, coordinated improvements across the entire global health system.[4]

Aligning Global Investment

The initiative's access agenda aims to strengthen the market ecosystem needed to ensure equitable access to safe, effective, and affordable medical devices and pharmaceuticals. The WHO is explicitly asking governments, private funders, and the pharmaceutical industry to align their financial investments around this single, unified goal.[1][4][6]

"This roadmap brings together research, medicines, clinical guidance, health systems and political action so that a woman's chances of surviving pregnancy and having a baby do not depend on where she lives," Allotey said, underscoring the fundamental equity issue at the heart of the new global strategy.[1][2]

To support these ambitious objectives, the WHO will establish a dedicated Steering Group to review existing coordination mechanisms across various professional medical organizations. The primary aim is to harmonize clinical recommendations, reduce areas of inconsistency, and ensure that all global guidance reflects the absolute best available scientific evidence.[4]

By setting clear, measurable expectations for each stakeholder group, the initiative seeks to transform its strategic vision into a highly coordinated global movement. The immediate next step requires national health ministries to adapt these global recommendations into fully funded, high-quality care programs tailored to their specific domestic populations.[1][4]

The initiative also directly addresses the specific, compounded needs of women affected by extreme poverty, active humanitarian crises, and severe geographical isolation. These vulnerable populations face particularly high risks of severe complications and death when standard emergency obstetric services are entirely out of reach.[1][5]

By aligning technical, policy, and investment priorities, the roadmap contributes directly to the United Nations Sustainable Development Goal targets for maternal and child health. The WHO expects these coordinated actions to drive measurable, life-saving reductions in maternal and newborn mortality by the 2035 target date.[4][6]